TB-500 has been developed to leverage the benefits of thymosin beta-4, focusing on enhancing tissue regeneration, reducing inflammation, and promoting overall recovery
It is not intended for human therapeutic, diagnostic, or clinical use.
primary efficacy goal was not met A published trial duration does not validate a different route, dose, or community cycle
Important context: Most published research on BPC-157 and TB-500 is in animal models
About PatientFi With PRIVI, you can access fully customized treatment plans through convenient monthly membership payments
The FDA is reviewing the peptide for ulcerative colitis, a chronic inflammatory bowel disease, but its often marketed for muscle and tissue recovery